drugset
Drugs / MAGE-A3
last change Jul 2018 re-read 9 days ago

MAGE-A3

Vaccine

Developed for
head and neck squamous cell carcinoma · plasma cell myeloma · melanoma
Investigated by
National Institute of Dental and Craniofacial Research (NIDCR) · University of Arkansas · University of Maryland, Baltimore

Trials 2

today NCT00257738 · Ph 1 NCT00090493 · Ph 2/3
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00257738 Nov 2005 → Oct 2012 head and neck squamous cell carcinoma University of Maryland, Baltimore Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00090493 Jun 2004 → Jul 2007 plasma cell myeloma University of Arkansas Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT01437605 Comparator Oct 2011 → Jul 2018 melanoma H. Lee Moffitt Cancer Center and Research Institute Terminated No outcome recorded

News releases announcing trial results or a regulatory action · 7

DateIssuerRelease
2014-04-02 GlaxoSmithKline Results Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer gsk.com ↗
However, the pre-planned independent third-party analysis of a proportion of the datav (to identify a gene signature classifier) has concluded that assessment of the third co-primary endpoint is not feasible due to an insufficient treatment effect.
2014-04-02 Agenus Inc. Results Update On GSK’S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer agenusbio.com ↗
GSK announced that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.
2014-03-20 GlaxoSmithKline Results Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial gsk.com ↗
2014-03-20 Agenus Inc. Results GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-small Cell Lung Cancer Misses First Co-primary Endpoints agenusbio.com ↗
2013-09-05 GlaxoSmithKline Results The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial gsk.com ↗
2013-09-05 Agenus Inc. Results GSK’S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint agenusbio.com ↗
2012-12-20 Gliknik Inc. Results Gliknik Announces Interim Clinical Data From Use of Its Immunomodulator Drug Candidate in Multiple Myeloma Patients gliknik.com ↗
Based on the interim analysis, researchers saw a 180-day rate of complete or partial response of 96 percent.

All press releases naming this drug 8 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as MAGE-A3 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01437605 ↗
2

NCT00257738 ↗

NCT00090493 ↗
Modality Vaccine “MAGE-A3/HPV 16 Vaccine” NCT00257738 ↗
Route Subcutaneous “Administered Subcutaneously” NCT00257738 ↗